Quick Answer
Anixa Biosciences Inc reported Revenue (ASC 606) of $210.0 thousand for fiscal year 2023.
Anixa Biosciences Inc Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2023 | $210.0K | -59.0% |
| 2021 | $512.0K | +104.8% |
| 2019 | $250.0K | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| April 30, 2023 | $210.0K | — | -59.1% |
| January 31, 2021 | $513.0K | — | — |
- Anixa Biosciences Inc showed a decrease of -59.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2019–2023 period, Anixa Biosciences Inc’s revenue (asc 606) has declined by 16.0% (from $250.0 thousand to $210.0 thousand).
- The most recent figure is from Anixa Biosciences Inc’s fiscal year 2024 report (Form 10-K), filed with the SEC on January 10, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: